SPARC surges on incorporating wholly owned subsidiary in Delaware
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Sun Pharma Advanced Research Company is currently trading at Rs. 224.90, up by 2.30 points or 1.03% from its previous closing of Rs. 222.60 on the BSE.
The scrip opened at Rs. 220.90 and has touched a high and low of Rs. 231.20 and Rs. 220.90 respectively. So far 55188 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 265.75 on 09-Nov-2022 and a 52 week low of Rs. 160.50 on 21-Mar-2023.
Last one week high and low of the scrip stood at Rs. 235.20 and Rs. 220.90 respectively. The current market cap of the company is Rs. 7356.90 crore.
The promoters holding in the company stood at 65.67%, while Institutions and Non-Institutions held 4.28% and 30.06% respectively.
Sun Pharma Advanced Research Company (SPARC) has incorporated a wholly owned subsidiary (WOS) namely ‘SPARCLIFE Inc.’ in Delaware, US. The main object of the Company is to obtain the services of the WOS which would engage a team of seasoned professionals based in US who coordinates, reviews and monitors the global clinical trials being conducted through various CROs in US by the Company.
Sun Pharma Advanced Research Company (SPARC) is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
